The Mayo Clinic says there's a new implantable device that could allow people with epilepsy to take control of their seizures.
The device detects abnormal activity in the brain and delivers subtle levels of electrical stimulation to normalize brain activity before a person has a seizure. The treatment is FDA-approved and is available at all Mayo Clinic sites.
The NeuroPace RNS System is used as an adjunctive therapy in reducing the frequency and severity of seizures in people 18 years of age or older with partial onset seizures who:
1. Have undergone diagnostic testing that localized no more than two epileptogenic foci
2. Are refractory to two or more antiepileptic medications
3. Currently have frequent and disabling seizures, including motor partial seizures, complex partial seizures and/or secondarily generalized seizures.
NeuroPace, Inc. says the treatment has been effectively demonstrated in patients who average three or more disabling seizures per month over the three most recent months (with no month with fewer than two seizures).
It has not been evaluated in patients with less frequent seizures. It is estimated that about 400,000 people in the U.S. meet these criteria and may benefit from treatment with the RNS System.
Mayo Clinic sites in Minnesota, Arizona and Florida all took part in clinical trials and have enrolled the highest number of patients into trials. Mayo Clinic also receives research support fro NeuroPace, and Dr. Richard Zimmerman has been paid as a consultant as a member of their medical advisory board.